Napabucasin granted Orphan Drug Designation

NAPABUCASIN received the Orphan Drug Designation from FDA in the treatment of pancreatic cancer. This is the second Orphan Drug Designation for napabucasin, an orally administered agent designed to inhibit cancer stemness pathways by targeting STAT3; the first designation was for gastric cancer including gastroesophageal junction cancer. Napabucasin, which is being developed by Boston Biomedical,...